Silo Pharma To Initiate Dose-Ranging Study Of Novel Intranasal Therapeutic SPC-15 For The Treatment Of PTSD
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma, Inc. (NASDAQ:SILO) has announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study, in collaboration with AmplifyBio, will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals. The final validation report is expected in 2024. If clinically successful, SPC-15 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval.
November 08, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's initiation of a dose-ranging study for its PTSD treatment SPC-15 could potentially lead to FDA approval. This could have a positive impact on the company's stock in the short term.
The initiation of a dose-ranging study for Silo Pharma's PTSD treatment SPC-15 is a significant step towards potential FDA approval. If the study is successful and the drug is approved, this could significantly increase the company's revenues and positively impact its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100